| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2146/AJHP080008 |
| P698 | PubMed publication ID | 18714107 |
| P2093 | author name string | Asad E Patanwala | |
| P2860 | cites work | The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients | Q61405306 |
| Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited | Q73434813 | ||
| Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity | Q74593077 | ||
| Recombinant activated factor VII for acute intracerebral hemorrhage | Q79685737 | ||
| Epidemiology of trauma deaths: a reassessment | Q28235326 | ||
| Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. | Q33377855 | ||
| Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding | Q35544621 | ||
| Safety profile of recombinant factor VIIa | Q35661521 | ||
| A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. | Q36068186 | ||
| Management of bleeding following major trauma: a European guideline | Q36296517 | ||
| Coagulopathy in the trauma patient | Q36314566 | ||
| Thromboembolic adverse events after use of recombinant human coagulation factor VIIa | Q36371024 | ||
| Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial | Q36392691 | ||
| Recombinant factor VIIa: safety and efficacy | Q36970113 | ||
| Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective | Q43055091 | ||
| The causes of death in conventional land warfare: implications for combat casualty care research. | Q44452641 | ||
| Factor VIIa for correction of traumatic coagulopathy | Q45130198 | ||
| Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force | Q45882922 | ||
| "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage | Q47256942 | ||
| Accuracy of weight and height estimation in an intensive care unit: Implications for clinical practice and research | Q47334427 | ||
| Thromboembolic complications associated with factor VIIa administration | Q48214116 | ||
| Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom | Q48637971 | ||
| Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. | Q48699527 | ||
| Clinical experience with recombinant activated factor VII in a series of 45 trauma patients. | Q50691181 | ||
| Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. | Q50758503 | ||
| Treatment of traumatic bleeding with recombinant factor VIIa. | Q55033461 | ||
| P433 | issue | 17 | |
| P304 | page(s) | 1616-1623 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Factor VIIa (recombinant) for acute traumatic hemorrhage | |
| P478 | volume | 65 |
| Q60998516 | Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma |
| Q37278074 | Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C. |
| Q41215308 | Intravenous hemostatic nanoparticles increase survival following blunt trauma injury |
| Q38148673 | Intravenous hemostats: challenges in translation to patients |
| Q24236583 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24245204 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q33876266 | Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications |
Search more.